0. Advocacy Webpage Graphics-Narrow -Standardize It 

There are many misconceptions about the disease of addiction, and a culture change is needed in this country to drive patients to the treatment options that have proven to be effective at reducing overdose deaths and supporting patients in remission and recovery. ASAM advocates for the use of nationally recognized guidelines and standards for the treatment of addiction and the dissemination of competency-based addiction education for all healthcare professionals.

The ASAM Criteria®, the most widely used and comprehensive set of guidelines for placement, continued stay and transfer/discharge of patients with addiction and co-occurring conditions, is a fundamental tool for the standardization of addiction medicine.

ASAM Level of Care Cert final


Transforming the Delivery of Substance Use Disorder Treatment in States

This slide presentation describes ASAM tools and resources that can help states transform the delivery of substance use disorder treatment.


Featured Public Policy Statements

0. doctor patient

Regulation of Office-Based Opioid Treatment

OBOT promotes the treatment of addiction in the primary care setting, but ASAM understands that the use of controlled substances to treat addiction introduces the possibility of misuse and diversion of the very medications used for treatment.
2. medical-recordscrop

Prescription Drug Monitoring Programs (PDMPs)

Find out more about PDMPs and ASAM's recommendations on how they should be regulated.


Joint Public Correctional Policy Statement on the Treatment of Opioid Use Disorders for Justice Involved Individuals

Learn more about how ASAM and the American Correctional Association (ACA) are supporting the use of evidence-based practices for the treatment of opioid use disorders in correctional settings.

"By implementing a quality-driven national addiction treatment infrastructure, we can empower patients and their families with information on how to identify and access high-quality treatment."

-Kelly Clark, MD, MBA, DFASAM
Immediate-Past President of ASAM



Appropriate Use of Drug Testing in Clinical Addiction Medicine

Provides guidance about the effective use of drug testing in the identification, diagnosis, treatment and promotion of recovery for patients with, or at risk for, addiction.


The ASAM National Practice Guideline

The ASAM National Practice Guideline and associated resources provide information on evidence-based treatment of opioid use disorder.


Confidentiality (42 CFR Part 2)

Learn how ASAM continues to call for needed privacy protections as 42 CFR Part 2 regulations and the underlying statute are updated. 

Related News


The US Department of Justice Drug Enforcement Administration Diversion Control Division Released Statement Clarifying the Use of Telemedicine for Medication Assisted Treatment (MAT)

by | Jun 04, 2018

On May 15, the Drug Enforcement Agency (DEA) Drug Diversion Division issued an email alert reiterating its position on the prescribing of controlled substances via telemedicine under the Ryan Haight Act of 2008.


The Ryan Haight Act states that to prescribe a controlled substance by means of the internet, the prescribing practitioner must have conducted an in-person medical evaluation. However, the law permits exceptions for controlled substance prescriptions via telemedicine under specific circumstances, including where the patients is being presented in a DEA-registered hospital or clinic. The Ryan Haight Act does exclude a number of circumstances where telemedicine has the potential to expand access to addiction treatment, such as excluding non-DEA-registered clinical settings where patients in underserved areas might seek access to a remote provider.


Below you can find the full text of the DEA notice: 


“Use of Telemedicine While Providing Medication Assisted Treatment (MAT)

Under the Ryan Haight Act of 2008, where controlled substances are prescribed by means of the Internet, the general requirement is that the prescribing Practitioner must have conducted at least one in-person medical evaluation of the patient. U.S.C. § 829(e). However, the Act provides an exception to this requirement. 21 USC § 829 (e)(3)(A). Specifically, a DEA-registered Practitioner acting within the United States is exempt from the requirement of an in-person medical evaluation as a prerequisite to prescribing or otherwise dispensing controlled substances by means of the Internet if the Practitioner is engaged in the practice of telemedicine and is acting in accordance with the requirements of 21 U.S.C. § 802(54).

Under 21 U.S.C. § 802(54)(A),(B), for most (DEA-registered) Practitioners in the United States, including Qualifying Practitioners and Qualifying Other Practitioners (“Medication Assisted Treatment Providers”), who are using FDA approved Schedule III-V controlled substances to treat opioid addiction, the term “practice of telemedicine” means the practice of medicine in accordance with applicable Federal and State laws, by a practitioner (other than a pharmacist) who is at a location remote from the patient, and is communicating with the patient, or health care professional who is treating the patient using a telecommunications system referred to in (42 C.F.R. § 410.78(a)(3)) which practice is being conducted:

A. while the patient is being treated by, and physically located in, a DEA-registered hospital or clinic registered under 21 U.S.C. § 823(f) of this title; and by a practitioner

-who is acting in the usual course of professional practice; 

-who is acting in accordance with applicable State law; and

-is registered under 21 U.S.C. § 823 (f) with the DEA in the State in which the patient is located.


B. while the patient is being treated by, and in the physical presence of, a DEA-registered practitioner

-who is acting in the usual course of professional practice; 

-who is acting in accordance with applicable State law; and

-is registered under 21 U.S.C. § 823 (f) with the DEA in the State in which the patient is located. 

Please be advised that the remote Practitioner engaged in the practice of telemedicine must be registered with the DEA in the state where they are physically located and in every state where their patient(s) is (are) physically located. 21 U.S.C. § 822 (e)(1); 21 C.F.R.§ 1301.12 (a); Notice 69478 Federal Register / Vol. 71, No. 231 / Friday, December 1, 2006.

Also be advised that all records for the prescribing of an FDA approved narcotic for the treatment of opioid addiction need to be kept in accordance with 21 C.F.R. § 1304.03(c), 21 C.F.R. § 1304.21(b), and with all other requirements of 21 C.F.R. Part 1300 to End.

Please note that while this document reflects DEA’s interpretation of the relevant provisions of the Controlled Substances Act (CSA) and DEA regulations, to the extent it goes beyond merely reiterating the text of law or regulations, it does not have the force of law and is not legally binding on registrants. Because this document is not a regulation that has the force of law, it may be rescinded or modified at DEA’s discretion.”